Institutional members access full text with Ovid®

Share this article on:

BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma

Lebbé, Celestea,b,c; How-Kit, Alexandred; Battistella, Maximee,b; Sadoux, Aurelief; Podgorniak, Marie-Pierref; Sidina, Irinaa; Pages, Cécilea; Roux, Jennifera; Porcher, Raphaelg,b; Tost, Jorgh; Mourah, Samiab,g,i

doi: 10.1097/CMR.0000000000000088
Letters to the Editor

aAP-HP, Department of Dermatology, Saint-Louis Hospital

bParis-Diderot University, Sorbonne Paris Cite

cINSERM U976

dLaboratory for Functional Genomics, Jean Dausset Fondation – CEPH

eAP-HP, Pathology Laboratory, Saint-Louis Hospital, INSERM UMR_S 1165

fAP-HP, Saint-Louis Hospital, Pharmacology-Genetic Laboratory

gDepartment of Biostatistics and Medical Data Processing, INSERM-U717

hLaboratory for Epigenetics and Environment, Genotyping National Center, CEA, Genomic Institute

iINSERM UMR-S 940, Paris, France

All supplementary digital content is available directly from the corresponding author.

Correspondence to Samia Mourah, PharmD, PhD, Laboratoire de Pharmacologie-Génétique and INSERM UMRS 940, Hôpital Saint-Louis; 27, rue Juliette Dodu, 75010 Paris, France Tel: +33 1 42 49 48 85; fax: +33 1 42 49 49 89;e-mail: samia.mourah@sls.aphp.fr

Received December 25, 2013

Accepted April 10, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins